Public procurement notice: Contract Award Notice
Published: 2025-06-11
Buyer: FrostPharma AB
Country: DK
Region: DK011
Contract type: Supplies
Procedure: Open procedure
CPV classification: 33600000: Pharmaceutical products
Estimated value: 225775606 EUR
Submission deadline: 2029-03-31
Award criteria: price

Technical requirements: Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals in the countries. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland. Under this tender group, the pharmaceuticals are tendered under each lot no. for the purpose of supplying the Contracting Authorities as 2 markets (Norway as 1 market and Denmark and Iceland as 1 market) see the tender specification. The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and Appendix 6.
Price is not the only award criterion and all criteria are stated only in the procurement documents.
Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no. 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints: Complaints of the tendering procedure must be lodged with the Complaints Board for Public Procurement within 6 months after the contracting entity has entered into a framework agreement calculated from the day after the day when the contracting entity has notified the affected applicants and tenderers, see section 7(2), para.(3) of the Act. Not later than at the time of lodging a complaint with the Danish Complaints Board for Public Procurement, the complainant must notify the contracting authorities in writing that a complaint has been lodged with the Danish Complaints Board for Public Procurement and whether the complaint was lodged during the standstill period, see section 6(4) of the Act. In cases where the complaint was not lodged within the standstill period, the complainant must furthermore indicate whether a suspensory effect of the complaint has been requested, see clause 6(4) of the Act.
ATC Code: J01CA01, 
Generic Name: Ampicillin, 
Pharmaceutical form: Injection Fluid,
Strength: 1 g,
Unit: 6 g,
Quantity in units: Norway: 35.000. 
ATC Code: J01CA01, 
Generic Name: Ampicillin,
Pharmaceutical form: Injection Fluid,
Strength: 2 g,
Unit: 6 g,
Quantity in units: Norway: 166.667. 
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 1 and 2, which are linked lot numbers. 
If there is only one compliant tender for either lot numbers 1 or 2, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. 
If there are several compliant tenders for both lot numbers 1 and 2, the award under lot number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 1 and 2, and there are several compliant tenders for both lot numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 1, since the framework agreement for lot number 2 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. 
If there is only one compliant tender for both lot numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 1 and 2. 
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Contracting Authorities shall be entitled to extend the framework agreement up to two times for each pharmaceutical on unchanged terms and conditions by up to 12 months. See Framework Agreement section 8.2.


Winner: Baxter A/S
Award value: 33696648
Number of bids: 4